Back to search
Primary Immunodeficiencies (PID)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Primary Immunodeficiencies (PID) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Primary Immunodeficiencies (PID) trials you may qualify forBackground: \- Researchers are interested in studying disorders that make individuals more susceptible to fungal infections, specifically infections with the C…
This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary…
This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants follo…
This is a phase III, non-randomized clinical trial (VIP Study) designed to assess the safety and efficacy of V-IMMUNE®, a 5% human normal immunoglobulin prepara…
All patients will receive the investigational medicinal product BP-SCIG 20%, solution for subcutaneous administration, manufactured by BIOPHARMA PLASMA LLC. A l…
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen pai…
This study will assess the relative safety, tolerability, and participant satisfaction in participants using the rapid manual push method with Cutaquig®. The hy…
The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.